Curis Inc CRIS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Curis to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on November 12, 2026
Curis, Inc. Announces Pricing of $8.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules with Existing Healthcare Focused Institutional Investors
Curis, Inc. Announces Pricing of $5.6 Million Public Offering
Trading Information
- Previous Close Price
- $0.85
- Day Range
- $0.77–0.90
- 52-Week Range
- $0.35–28.00
- Bid/Ask
- $0.85 / $0.87
- Shares Outstanding
- 6.68M
- Market Cap
- $1.89M
- Volume/Avg
- 142,632 / 4M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.23
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 24
- Website
- https://www.curis.com
Valuation
Metric | CRIS |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.35 |
Price/Sales | 0.23 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | CRIS |
|---|---|
Quick Ratio | 0.37 |
Current Ratio | 0.49 |
Interest Coverage | −10.05 |
Quick Ratio
CRIS
Profitability
Metric | CRIS |
|---|---|
Return on Assets (Normalized) | −181.20% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −8,843.69% |
Return on Assets
CRIS
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|$P^qHVp | LOCK|^y%$ | $138B | |||
| Moderna Inc MRNA | LOCK|kKNnLp< | LOCK|zC | $96B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|hkl%@w$ | LOCK|Q@?Q | $93B | |||
| argenx SE ADR ARGX | LOCK|^>^%^$ | LOCK|f@! | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|$P#rKf | LOCK|!Y | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|%wvLLmb | LOCK|Ht@Kq | $30B | |||
| Incyte Corp INCY | LOCK|QtxPtH@ | LOCK|s@ | $24B | |||
| BioNTech SE ADR BNTX | LOCK|#?HXZp | LOCK|%Wv | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|$<JSfF# | LOCK|<Lfbw | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|b#!M?k | LOCK|!l | $15B |
United States